Danisco and Fonterra have extended their licensing agreement for two probiotic bacteria cultures.
Danisco’s agreement covers the production and marketing of their probiotic strains, HOWARU Bifido and Rhamnosus, with the new terms extending from five to 10 years.
The agreement also includes global access to dairy products, liquid and powdered beverages, dietary supplements, meats, cheeses, cereals, confectionery and straws.
In addition, there will no longer be restrictions on therapeutic fields, thus broadening the scope for the development of clinical studies and health claims.
“The expanded terms mean Danisco can offer HOWARU Bifido and Rhamnosus, two of the most highly documented probiotic strains on the market, to customers anywhere in the world for a total range of applications and benefits,” Scott Bush, Danisco marketing health and nutrition vice president, said.
Danisco first began licensing Fonterra-developed probiotics in 2001, which have since been developed at Fonterra’s Research Centre in New Zealand.